T0	Participants 33 152	antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
T1	Participants 323 324	.
T2	Participants 325 554	MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy with zidovudine/lamivudine and lopinavir/ritonavir in antiretroviral-naïve patients
T3	Participants 572 709	of 136 antiretroviral-naïve patients, with a CD4 cell count above 100 cells/microL and a plasma HIV RNA below 100,000 HIV-1 RNA copies/mL
T4	Participants 842 846	53).
T5	Participants 847 935	We focus here on patients in the lopinavir/ritonavir monotherapy arm followed to week 96